ATF3 repression of BCL-XL determines apoptotic sensitivity to HDAC inhibitors across tumor types

Chüeh, A C; Tse, J W T; Dickinson, M; Ioannidis, P; Jenkins, L; Togel, L; Tan, B S; Luk, I; Davalos-Salas, M; Nightingale, R; Thompson, M R; Williams, B R G; Lessene, G; Lee, E F; Fairlie, W D; Dhillon, Amardeep; Mariadason, J M

File(s) under permanent embargo

ATF3 repression of BCL-XL determines apoptotic sensitivity to HDAC inhibitors across tumor types

journal contribution

posted on 2017-09-01, 00:00 authored by A C Chüeh, J W T Tse, M Dickinson, P Ioannidis, L Jenkins, L Togel, B S Tan, I Luk, M Davalos-Salas, R Nightingale, M R Thompson, B R G Williams, G Lessene, E F Lee, W D Fairlie, Amardeep DhillonAmardeep Dhillon, J M Mariadason

ATF3 repression of BCL-XL determines apoptotic sensitivity to HDAC inhibitors across tumor types

History

Journal

Clinical Cancer Research

Volume

23

Issue

18

Pagination

5573 - 5584

Publisher

Association for Cancer Research

Location

Denville, N.J.

Publisher DOI

https://doi.org/10.1158/1078-0432.CCR-17-0466

ISSN

1078-0432

eISSN

1557-3265

Language

eng

Publication classification

C1 Refereed article in a scholarly journal

Usage metrics

Keywords

Science & Technology Life Sciences & Biomedicine Oncology HISTONE DEACETYLASE INHIBITORS ACTIVATING TRANSCRIPTION FACTOR-3 COLON-CANCER CELLS TRAIL-MEDIATED APOPTOSIS HUMAN LEUKEMIA-CELLS UP-REGULATION HDAC INHIBITORS GENE-EXPRESSION MELANOMA-CELLS ER STRESS

Licence

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

File(s) under permanent embargo

ATF3 repression of BCL-XL determines apoptotic sensitivity to HDAC inhibitors across tumor types

History

Journal

Volume

Issue

Pagination

Publisher

Location

Publisher DOI

ISSN

eISSN

Language

Publication classification

Usage metrics

Categories

Keywords

Licence

Exports